Professor Catherine GodsonFull Professor
Catherine is Full Professor of Molecular Medicine at UCD School of Medicine, Director of the UCD Diabetes Complications Research Centre, and Fellow at UCD Conway Institute.
She leads a group of investigators whose research focuses on innate immunity and chronic complications of diabetes. Amongst her research contributions was the discovery that lipoxins, endogenously generated lipid mediators, promote the resolution of inflammation. These molecules are now being developed towards clinical application through Attenuate Therapeutics, a company that she co-founded in 2022.
Together with colleagues at UCD and The Mater University and Beaumont Hospitals she has identified several novel mediators of progression and potential regression in diabetic kidney disease.
In recognition of her outstanding career in the field of inflammation and for helping the scientific advancement of women scientists in the field, she received the Women in Science Award of The International Congress of Inflammation, Sydney Australia 2019.
She was awarded The Graves Medal of The Royal Academy of Medicine, 2021, and in 2022 she received the Eicosanoid Research Foundation Outstanding Achievement award for her research achievements on the vascular complications of diabetes and the resolution of inflammation.
Catherine has served on the Health Research Board, The European Medical Research Council and The Wellcome Trust’s Physiological Sciences Committee. She was elected to membership of The Royal Irish Academy in 2011 and elected Secretary for Science of the academy in 2020. She is a Trustee of Bart’s Charity, London and was recently appointed to the board of the Irish Research Council.is Science Secretary of the Royal Irish Academy. She is Co-Chair of The American Society for Nephrology 2022 Annual meeting committee.